Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Autoimmune Disorders

Free Subscription Articles published in Lancet Retrieve available abstracts of 65 articles: HTML format Text format

Single Articles

March 2018
1. KAPPOS L, Bar-Or A, Cree BAC, Fox RJ, et al
   Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
   Lancet. 2018 Mar 22. pii: S0140-6736(18)30475.
   PubMed     Text format     Abstract available
   
   
   
2. THOMPSON AJ, Baranzini SE, Geurts J, Hemmer B, et al
   Multiple sclerosis.
   Lancet. 2018 Mar 22. pii: S0140-6736(18)30481.
   PubMed     Text format     Abstract available
   
   
   
3. THE LANCET
   End of the road for daclizumab in multiple sclerosis.
   Lancet. 2018;391:1000.
   PubMed     Text format    
   
   
   
4. LAI ZW, Kelly R, Winans T, Marchena I, et al
   Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
   Lancet. 2018 Mar 15. pii: S0140-6736(18)30485.
   PubMed     Text format     Abstract available
   
   
   
5. FERNANDEZ DR, Crow MK
   CD8 T cells and mTOR: new concepts and targets for systemic lupus erythematous.
   Lancet. 2018 Mar 15. pii: S0140-6736(18)30544.
   PubMed     Text format    
   
   
   December 2017
6. TSUDA K, Tanimoto T, Mori J, Kosugi K, et al
   Targeted-release budesonide therapy for IgA nephropathy.
   Lancet. 2017;390:2625.
   PubMed     Text format    
   
   
   
7. FELLSTROM B, Barratt J, Floge J, Jardine A, et al
   Targeted-release budesonide therapy for IgA nephropathy - Authors' reply.
   Lancet. 2017;390:2625-2626.
   PubMed     Text format    
   
   
   October 2017
8. GREEN AJ, Gelfand JM, Cree BA, Bevan C, et al
   Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
   Lancet. 2017 Oct 10. pii: S0140-6736(17)32346.
   PubMed     Text format     Abstract available
   
   
   
9. RUBIN R
   Mary Crow: leader in research on systemic lupus erythematosus.
   Lancet. 2017;390:1636.
   PubMed     Text format    
   
   
   March 2017
10. WYATT RJ
    Are we ready for targeted therapy for IgA nephropathy?
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30820.
    PubMed     Text format    
    
    
    
11. FELLSTROM BC, Barratt J, Cook H, Coppo R, et al
    Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Lancet. 2017 Mar 28. pii: S0140-6736(17)30550.
    PubMed     Text format     Abstract available
    
    
    
12. ATKINS H, Freedman MS
    Immunoablation and aHSCT for aggressive multiple sclerosis - Authors' reply.
    Lancet. 2017;389:908.
    PubMed     Text format    
    
    
    
13. HARRIS M, Cossburn M, Gregory R
    Immunoablation and aHSCT for aggressive multiple sclerosis.
    Lancet. 2017;389:907-908.
    PubMed     Text format    
    
    
    January 2017
14. BUENZ EJ, Parry GJ, Ranta A
    Guillain-Barre syndrome: surveillance and cost of treatment strategies.
    Lancet. 2017;389:253.
    PubMed     Text format    
    
    
    
15. WILLISON HJ, Jacobs BC, van Doorn PA
    Guillain-Barre syndrome: surveillance and cost of treatment strategies - Authors' reply.
    Lancet. 2017;389:253-254.
    PubMed     Text format    
    
    
    
16. DURRHEIM DN
    Guillain-Barre syndrome: surveillance and cost of treatment strategies.
    Lancet. 2017;389:252-253.
    PubMed     Text format    
    
    
    
17. CHEN H, Kwong JC, Copes R, Tu K, et al
    Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study.
    Lancet. 2017 Jan 4. pii: S0140-6736(16)32399.
    PubMed     Text format     Abstract available
    
    
    December 2016
18. EL-KHATIB FH, Balliro C, Hillard MA, Magyar KL, et al
    Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    Lancet. 2016 Dec 20. pii: S0140-6736(16)32567.
    PubMed     Text format     Abstract available
    
    
    November 2016
19. COMI G, Radaelli M, Soelberg Sorensen P
    Evolving concepts in the treatment of relapsing multiple sclerosis.
    Lancet. 2016 Nov 23. pii: S0140-6736(16)32388.
    PubMed     Text format     Abstract available
    
    
    
20. ONTANEDA D, Thompson AJ, Fox RJ, Cohen JA, et al
    Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.
    Lancet. 2016 Nov 23. pii: S0140-6736(16)31320.
    PubMed     Text format     Abstract available
    
    
    
21. BROWNLEE WJ, Hardy TA, Fazekas F, Miller DH, et al
    Diagnosis of multiple sclerosis: progress and challenges.
    Lancet. 2016 Nov 23. pii: S0140-6736(16)30959.
    PubMed     Text format     Abstract available
    
    
    September 2016
22. BOLINDER J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, et al
    Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.
    Lancet. 2016 Sep 9. pii: S0140-6736(16)31535.
    PubMed     Text format     Abstract available
    
    
    July 2016
23. LAZARUS C, Guichard M, Philippe JM, Paux T, et al
    The French experience of the threat posed by Zika virus.
    Lancet. 2016;388:9-11.
    PubMed     Text format    
    
    
    
24. TARANTINO MD, Bussel JB, Blanchette VS, Despotovic J, et al
    Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Lancet. 2016;388:45-54.
    PubMed     Text format     Abstract available
    
    
    
25. CHATURVEDI S, McCrae KR
    Treatment of chronic immune thrombocytopenia in children with romiplostim.
    Lancet. 2016;388:4-6.
    PubMed     Text format    
    
    
    June 2016
26. FONTANET A, Cao-Lormeau VM, Dub T, Mallet HP, et al
    Association between Guillain-Barre syndrome and Zika virus infection - Authors' reply.
    Lancet. 2016;387:2600.
    PubMed     Text format    
    
    
    
27. BAUTISTA LE, Sethi AK
    Association between Guillain-Barre syndrome and Zika virus infection.
    Lancet. 2016;387:2599-600.
    PubMed     Text format    
    
    
    
28. AVELINO-SILVA VI, Martin JN
    Association between Guillain-Barre syndrome and Zika virus infection.
    Lancet. 2016;387:2599.
    PubMed     Text format    
    
    
    
29. RUPERTO N, Pistorio A, Ravelli A, Angioloni S, et al
    The PRINTO juvenile dermatomyositis trial - Authors' reply.
    Lancet. 2016;387:2601.
    PubMed     Text format    
    
    
    
30. DALE A, Milosevic I, Goldacre B
    The PRINTO juvenile dermatomyositis trial.
    Lancet. 2016;387:2600-1.
    PubMed     Text format    
    
    
    
31. ATKINS HL, Bowman M, Allan D, Anstee G, et al
    Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Lancet. 2016 Jun 8. pii: S0140-6736(16)30169.
    PubMed     Text format     Abstract available
    
    
    
32. DORR J
    Haemopoietic stem-cell transplantation for multiple sclerosis: what next?
    Lancet. 2016 Jun 8. pii: S0140-6736(16)30377.
    PubMed     Text format    
    
    
    
33. ZOMA AA
    Clinical overlap in proximal artery stenosis: two disorders or one?
    Lancet. 2016;387:2350.
    PubMed     Text format    
    
    
    
34. JAIN P, Ruchin P, Suttie J
    Proximal pulmonary artery stenosis: a rare manifestation of granulomatosis with polyangiitis.
    Lancet. 2016;387:2349-50.
    PubMed     Text format    
    
    
    
35. REWERS M, Ludvigsson J
    Environmental risk factors for type 1 diabetes.
    Lancet. 2016;387:2340-8.
    PubMed     Text format     Abstract available
    
    
    
36. POCIOT F, Lernmark A
    Genetic risk factors for type 1 diabetes.
    Lancet. 2016;387:2331-9.
    PubMed     Text format     Abstract available
    
    
    
37. RUBIN R
    Kevan Herold: untangling type 1 diabetes in the clinic and the lab.
    Lancet. 2016;387:2283.
    PubMed     Text format    
    
    
    
38. RUBIN R
    Profile: Type 1 Diabetes TrialNet.
    Lancet. 2016;387:2280.
    PubMed     Text format    
    
    
    
39. 
    Towards a better understanding of type 1 diabetes.
    Lancet. 2016;387:2264.
    PubMed     Text format    
    
    
    May 2016
40. FLOEGE J, Amann K
    Primary glomerulonephritides.
    Lancet. 2016;387:2036-48.
    PubMed     Text format     Abstract available
    
    
    
41. GUILLEVIN L, Regent A
    Treating giant-cell arteritis: is IL-6 the cytokine to target?
    Lancet. 2016;387:1882-1883.
    PubMed     Text format    
    
    
    April 2016
42. BARNETT R
    Systemic lupus erythematosus.
    Lancet. 2016;387:1711.
    PubMed     Text format    
    
    
    
43. BRASIL P, Sequeira PC, Freitas AD, Zogbi HE, et al
    Guillain-Barre syndrome associated with Zika virus infection.
    Lancet. 2016;387:1482.
    PubMed     Text format    
    
    
    
44. SNYDER A
    John Kurtzke.
    Lancet. 2016;387:1370.
    PubMed     Text format    
    
    
    March 2016
45. DE LEO S, Lee SY, Braverman LE
    Hyperthyroidism.
    Lancet. 2016 Mar 30. pii: S0140-6736(16)00278.
    PubMed     Text format     Abstract available
    
    
    
46. VILLIGER PM, Adler S, Kuchen S, Wermelinger F, et al
    Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2016 Mar 4. pii: S0140-6736(16)00560.
    PubMed     Text format     Abstract available
    
    
    
47. MECHARLES S, Herrmann C, Poullain P, Tran TH, et al
    Acute myelitis due to Zika virus infection.
    Lancet. 2016 Mar 3. pii: S0140-6736(16)00644.
    PubMed     Text format    
    
    
    February 2016
48. WILLISON HJ, Jacobs BC, van Doorn PA
    Guillain-Barre syndrome.
    Lancet. 2016 Feb 29. pii: S0140-6736(16)00339.
    PubMed     Text format     Abstract available
    
    
    
49. CAO-LORMEAU VM, Blake A, Mons S, Lastere S, et al
    Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study.
    Lancet. 2016 Feb 29. pii: S0140-6736(16)00562.
    PubMed     Text format     Abstract available
    
    
    
50. SMITH DW, Mackenzie J
    Zika virus and Guillain-Barre syndrome: another viral cause to add to the list.
    Lancet. 2016 Feb 29. pii: S0140-6736(16)00564.
    PubMed     Text format    
    
    
    
51. SARGENT J
    Rheumatology--a call for papers.
    Lancet. 2016;387:519.
    PubMed     Text format    
    
    
    January 2016
52. SEGAL BM, Stuve O
    Primary progressive multiple sclerosis-why we are failing.
    Lancet. 2016 Jan 27. pii: S0140-6736(16)00158.
    PubMed     Text format    
    
    
    
53. LUBLIN F, Miller DH, Freedman MS, Cree BA, et al
    Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2016 Jan 27. pii: S0140-6736(15)01314.
    PubMed     Text format     Abstract available
    
    
    
54. MILOSEVIC I, Slade E, Drysdale H
    Eltrombopag for chronic immune thrombocytopenia.
    Lancet. 2016;387:336.
    PubMed     Text format    
    
    
    
55. GRAINGER JD
    Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
    Lancet. 2016;387:336-7.
    PubMed     Text format    
    
    
    December 2015
56. FEEHALLY J
    Glomerulonephritis from a chronically infected implanted device.
    Lancet. 2015;386:2364.
    PubMed     Text format    
    
    
    
57. SARITAS T, Brandenburg V, Federico G, Grone HJ, et al
    Glomerulonephritis triggered by a chronically infected left ventricular assist device.
    Lancet. 2015;386:2363-4.
    PubMed     Text format    
    
    
    November 2015
58. MIOSSEC P
    Progress in the treatment of juvenile dermatomyositis.
    Lancet. 2015 Nov 27. pii: S0140-6736(15)01023.
    PubMed     Text format    
    
    
    
59. RUPERTO N, Pistorio A, Oliveira S, Zulian F, et al
    Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.
    Lancet. 2015 Nov 27. pii: S0140-6736(15)01021.
    PubMed     Text format     Abstract available
    
    
    
60. DHALIWAL HS, Sekhon GS, Rai N, Nampoothiri RV, et al
    An unusual medical cause of abdominal pain diagnosed by urological abnormalities.
    Lancet. 2015 Nov 13. pii: S0140-6736(15)00806.
    PubMed     Text format    
    
    
    
61. LOCKWOOD DN, Lambert SM, Walker SL
    Cutaneous nodules with positive autoantibodies: diagnostic pitfalls.
    Lancet. 2015;386:1916.
    PubMed     Text format    
    
    
    
62. ZHANG G, Jin H, Chen H, Lu Q, et al
    Cutaneous nodules with positive autoantibodies: histoid leprosy.
    Lancet. 2015;386:1915-6.
    PubMed     Text format    
    
    
    October 2015
63. KIPFER S, Frigerio S, Hench J, Aussy A, et al
    Immune-mediated necrotising myopathy linked to statin use.
    Lancet. 2015;386:e26.
    PubMed     Text format    
    
    
    
64. NEUNERT CE, Grace RF
    Thrombopoietin-receptor agonists in children with immune thrombocytopenia.
    Lancet. 2015;386:1606-9.
    PubMed     Text format    
    
    
    
65. GRAINGER JD, Locatelli F, Chotsampancharoen T, Donyush E, et al
    Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Lancet. 2015;386:1649-58.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: